Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer

被引：0
|
作者：
Boccardo, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Rubagotti, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Guglielmini, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Sismondi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Farris, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Amadori, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Agostara, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Gambi, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Catalano, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Faedi, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[2] Univ Mauriziano, Molinette Mauriziano Hosp, Turin, Italy
[3] Univ Sassari, I-07100 Sassari, Italy
[4] Tumor Inst Meldola, Forli, Italy
[5] M Ascoli Hosp, Palermo, Italy
[6] Infermi Hosp, Faenza, Italy
[7] Gen Hosp Pesaro, Pesaro, Italy
[8] Osped Gen Provinciale M Bufalini, Cesena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11521
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CLINICAL CONTROLLED TRIAL IN ADVANCED BREAST-CANCER - CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CMF+T (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, TAMOXIFEN)
    HINDY, I
    NEOPLASMA, 1985, 32 (03) : 381 - 387
  • [22] Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome
    Penault-Llorca, F.
    Radosevic-Robin, N.
    Abrial, C.
    Dauplat, M-M
    Weber, B.
    Mouret-Reynier, M-A
    Gligorov, J.
    Tredan, O.
    Privat, M.
    Uhrhammer, N.
    Desrichard, A.
    Bidet, Y.
    Cayre, A.
    Aube, C.
    Romero, P.
    Kwiatkowski, F.
    Chalabi, N.
    Bignon, Y-J
    Chollet, P.
    Nabholtz, J-M
    CANCER RESEARCH, 2013, 73
  • [23] DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF VERSUS EPIRUBICIN, CMF AND WEEKLY DOCETAXEL OR PACLITAXEL FOLLOWED BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER
    Fountzilas, G.
    Gogas, H.
    Pavlidis, N.
    Eleftheraki, A.
    Skarlos, D.
    Koutras, A.
    Timotheadou, E.
    Papandreou, C.
    Pectasides, D.
    Dimopoulos, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 95 - 95
  • [24] Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
    Martin, Miguel
    Rodriguez-Lescure, Alvaro
    Ruiz, Amparo
    Alba, Emilio
    Calvo, Lourdes
    Ruiz-Borrego, Manuel
    Munarriz, Blanca
    Rodriguez, Cesar A.
    Crespo, Carmen
    de Alava, Enrique
    Lopez Garcia-Asenjo, Jose Antonio
    Dolores Guitian, Maria
    Almenar, Sergio
    Fernando Gonzalez-Palacios, Jesus
    Vera, Francisco
    Palacios, Jose
    Ramos, Manuel
    Gracia Marco, Jose Manuel
    Lluch, Ana
    Alvarez, Isabel
    Angel Segui, Miguel
    Ignacio Mayordomo, Jose
    Anton, Antonio
    Manuel Baena, Jose
    Plazaola, Arrate
    Modolell, Alfonso
    Pelegri, Amadeu
    Ramon Mel, Jose
    Aranda, Enrique
    Adrover, Encarna
    Valero Alvarez, Jose
    Garcia Puche, Jose Luis
    Sanchez-Rovira, Pedro
    Gonzalez, Sonia
    Manuel Lopez-Vega, Jose
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (11): : 805 - 814
  • [25] Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
    Chau Dang
    Current Breast Cancer Reports, 2009, 1 (1) : 1 - 2
  • [26] Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
    Martin, M.
    Rodriquez-Lescure, A.
    Ruiz, A.
    CURRENT BREAST CANCER REPORTS, 2009, 1 (01) : 1 - 2
  • [27] Neoadjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller, W.
    Mazhar, D.
    Ward, R.
    Lowdell, C.
    Dudley, S.
    Sami, S.
    Carlo, P.
    Charles, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S157 - S157
  • [28] Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer
    Baldini, E
    Gardin, G
    Giannessi, PG
    Evangelista, G
    Roncella, M
    Prochilo, T
    Collecchi, P
    Rosso, R
    Lionetto, R
    Bruzzi, P
    Mosca, F
    Conte, PF
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 227 - 232
  • [29] Nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in neoadjuvant chemotherapy for resectable breast cancer: Phase II trial
    Kin, T.
    Fujihara, M.
    Yoshimura, Y.
    Kajiwara, Y.
    Ito, M.
    Ohtani, S.
    Taniguchi, K.
    Morito, T.
    Takada, S.
    Ichimura, K.
    BREAST, 2017, 32 : S79 - S80
  • [30] Short-term health-related quality of life with epirubicin and cyclophosphamide versus 5-fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy in Turkish patients with operable breast cancer.
    Demirkan, HMB
    Yavuzsen, T
    Dirioz, M
    Demiral, Y
    Alacacioglu, A
    Baskan, Z
    Fidaner, H
    Alakavuklar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 97S - 97S
12345